TORONTO, Dec. 12, 2017 /CNW/ -
https://www.youtube.com/watch?v=Bgu6wgtGuJc
The View from the C-Suite video interview series highlights the
unique perspectives of listed companies on Toronto Stock Exchange
and TSX Venture Exchange. Videos provide insight into how
company executives think in the current business environment.
To see the latest View from the C-Suite videos
visit www.tmxmoney.com/en/news/csuite.html.
About Novoheart Holdings (TSXV:NVH):
Novoheart is a global stem cell biotechnology company
pioneering an array of next-generation human heart tissue
prototypes. It is the first company in the world to have engineered
miniature living human heart pumps that can revolutionize drug
discovery, helping to save time and money for developing new
therapeutics.
Also known as 'human heart-in-a-jar', Novoheart's
bioartificial human heart constructs are created using
state-of-the-art stem cell and bioengineering approaches, and are
utilized by drug developers for accurate preclinical testing as to
the effectiveness and safety of new drugs, maximizing the successes
in drug discovery whilst minimizing costs and harm caused to
patients.
About TMX Group (TSX: X)
TMX Group's key subsidiaries operate cash and derivative markets
and clearinghouses for multiple asset classes including equities,
fixed income and energy. Toronto Stock Exchange, Venture
Exchange, TSX Alpha Exchange, The Canadian Depository for
Securities, Montréal Exchange, Canadian Derivatives
Clearing Corporation, and other TMX Group companies provide listing
markets, trading markets, clearing facilities, depository services,
data products and other services to the global financial community.
TMX Group is headquartered in Toronto and operates offices across
Canada (Montréal, Calgary and Vancouver), in key U.S. markets (New York, Houston) as well as in London, Beijing, Singapore and Israel. For more information about TMX Group,
visit our website at http://www.tmx.com. Follow TMX Group on
Twitter: @TMXGroup.
SOURCE TMX Group Limited